Healthcare / Medical Instruments & SuppliesShanghai
$43.61
-0.17 (-0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $18.3M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.4B
P/E
31.8x
↑EV/EBITDA
17.3x
↑ROE
9.6%
↑Gross Margin
63.5%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+36.8%
FCF CAGR
—
FCF margin
16.6%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.48B · net income $268.2M · FCF $246.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.48B | $1.48B | $1.41B | $951.2M | $579.5M |
| Net Income | $268.2M | $268.2M | $388.4M | $304.0M | $232.7M |
| EBITDA | $481.0M | $481.0M | $585.0M | $414.2M | $309.4M |
| EPS | 1.40 | 1.40 | 2.05 | 1.60 | 1.23 |
| Gross Margin | 63.5% | 63.5% | 66.2% | 75.7% | 84.8% |
| Operating Margin | 27.2% | 27.2% | 33.2% | 34.3% | 42.6% |
| Net Margin | 18.1% | 18.1% | 27.5% | 32.0% | 40.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.24 | 0.18 | 0.09 |
| Current Ratio | 3.11 | 3.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $246.0M | $246.0M | $18.3M | $-157.7M | $-20.9M |
| Returns | |||||
| ROE | 9.6% | 9.6% | 16.1% | 14.3% | 12.5% |
| Valuation | |||||
| P/E | 31.83 | 31.83 | 45.15 | 101.66 | 191.23 |
| EV/EBITDA | 17.27 | 17.27 | 30.34 | 74.25 | 143.18 |
| P/B | 3.00 | 3.00 | 7.28 | 14.51 | 23.92 |
| Growth & Yield | |||||
| Revenue Growth | 5.2% | 5.2% | 48.2% | 64.1% | — |
| EPS Growth | -31.7% | -31.7% | 28.1% | 30.3% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
40.3%
EPS terminal req.
$3.87
Spread vs growth
-72.0%
5Y implied EPS CAGR
27.3%
EPS terminal req.
$4.68
Spread vs growth
-59.0%
10Y implied EPS CAGR
18.3%
EPS terminal req.
$7.54
Spread vs growth
-50.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.7%
Start / end P/E
37.0x → 31.2x
EPS bridge
2.05 → 1.40
Residual
+5.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.